This research aims to determine how absolute cardiovascular risk impacts the efficacy of Lp(a)-guided aspirin therapy in primary prevention.
Conducted a randomized trial assessing aspirin therapy relevance based on absolute cardiovascular risk and Lp(a) levels.
Participants were screened for cardiovascular risk factors to tailor prevention strategies.
Outcome measures included incidence rates of cardiovascular events post-therapy.
Participants with elevated Lp(a) receiving aspirin showed a significant decrease in cardiovascular events compared to those not using aspirin, with a reduced risk of 30% (HR 0.70, 95% CI 0.55-0.89, p=0.002).
Absolute cardiovascular risk scores significantly improved treatment response, indicating better patient outcomes when risk factors were considered.